pharmaphorum

FEBRUARY 12, 2024

Changing Faces: Agency, consultancy, and investor hires from January 2024 highlights the recent hires and movements in prominent companies such as Permira, Cuttsy+Cuttsy, SV Health Investors, and Cure Ventures. Stay updated with the latest talent appointments in the industry.

110

110

Fierce Pharma

APRIL 15, 2024

Activist investor Shah Capital, which owns 6.7% of Novavax's stock, has claimed that the vaccine developer has been “historically mismanaged” as the firm tries to install new members | Activist investor Shah Capital, which owns 6.7%

Sales 75

Sales Vaccination Vaccine Development 75

Bio Pharma Dive

JANUARY 29, 2021

Investors feared an outright rejection for aducanumab. But the FDA moving its approval deadline back three months is a signal to some that the agency wants to approve Biogen's drug.

Drugs 267

Drugs 267

Bio Pharma Dive

JUNE 23, 2021

Under pressure from activist investors, the British drugmaker set lofty sales targets for a "new GSK" after a planned exit from consumer health. But shareholders will first face a dividend cut.

Sales 241

Sales 241

Bio Pharma Dive

APRIL 25, 2024

The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.

Medicine 166

Medicine Drugs 166

World of DTC Marketing

FEBRUARY 15, 2022

Biotechs need to think like marketers to cut through the noise and attract investors. The post For biotechs to attract investors think like marketers appeared first on World of DTC Marketing.com. Biotech startups are hurting for money as investments in biotech startups start to decline.

Marketing 224

Marketing Clinical Trials Clinical Trials Trials 224

Bio Pharma Dive

APRIL 26, 2024

Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.

Branding 166

Branding Drugs 166

Bio Pharma Dive

MAY 26, 2023

Investors struck deals worth $1.8 billion over the first three months of the year, down from $3.0 billion across the start of 2022.

130

130

BioPharma Reporter

DECEMBER 21, 2023

Here are five ADC players that have caught the eye of investors in the last 12 months. Antibody-drug conjugates (ADC) are booming in the biotech industry this year with mounting investment and M&A deals.

Antibody 98

Antibody Drugs Regulation Marketing 98

BioSpace

DECEMBER 6, 2023

In an R&D event on Thursday, the French pharma is trying to win over its investors by highlighting a dozen potential blockbusters and charting strong growth for the company through 2030.

101

101

Fierce Pharma

MARCH 1, 2024

In the latest shake-up amid waves of changes at Bayer, the company is planning to add new expertise to its board room, including a prominent activist investor. | The company's supervisory board proposed the appointments of activist investor Jeffrey Ubben, legal expert Lori Schecter and biotech leader Nancy Simonian, M.D.

74

74

Fierce Pharma

DECEMBER 21, 2023

Along with a new CEO, BioMarin will head into 2024 with three new board directors and a new strategy review committee after settling with activist investor Elliott Investment Management. Elliott Investment Management is one of BioMarin's largest investors with a stake worth more than $1 billion.

93

93

pharmaphorum

NOVEMBER 8, 2023

Activist investor Elliott turns its attention to BioMarin Phil.Taylor Wed, 08/11/2023 - 10:01 Bookmark this

104

104

BioSpace

NOVEMBER 7, 2023

Activist hedge fund investor Elliott Investment Management has bought over a $1 billion stake in BioMarin as the biotech grapples with a leadership change and disappointing sales of its hemophilia A gene therapy.

Sales 106

Sales Gene Therapy Gene 106

Pharmaceutical Technology

APRIL 24, 2024

At the Swiss Biotech Day conference, panelists at an investment talk discussed the current state of the Swiss investment landscape.

130

130

BioSpace

SEPTEMBER 13, 2023

In the largest biotech Series C financing so far this year, Generate:Biomedicines picked up new investors including Amgen and NVIDIA’s venture capital arm to advance its pipeline of 17 programs.

108

108

pharmaphorum

NOVEMBER 3, 2023

Scientists in the C-Suite: Attracting investors takes more than good science Mike.Hammerton Fri, 03/11/2023 - 08:00 Bookmark this

Scientist 110

Scientist 110

pharmaphorum

OCTOBER 15, 2023

Scientists in the C-suite: Attracting investors takes more than good science Mike.Hammerton Sun, 15/10/2023 - 19:45 Bookmark this

Scientist 114

Scientist 114

Fierce Pharma

SEPTEMBER 21, 2023

Long categorized as a takeover target, autoimmune disease specialist Aurinia Pharmaceuticals has remained independent, to the frustration of some investors who believe the Canadian company has not | Aurinia has responded to criticism from some investors who believe the company has not maximized its opportunity with lupus nephritis drug Lupkynis.

Drugs 96

Drugs 96

Fierce Pharma

AUGUST 30, 2023

After a tumultuous year of manufacturing hiccups, executive turnover and dwindling revenues, Catalent is handing the reins to activist investor Elliott Management. The CDMO giant struck a cooperation agreement with the activist investor group as it announced fourth-quarter revenues and unveiled a sweeping governance shakeup.

Manufacturing 87

Manufacturing 87

Bio Pharma Dive

DECEMBER 19, 2023

The biotechnology company’s share price fell more than 10% Tuesday after the disclosure of more data from a small study.

Gene Therapy 281

Gene Therapy Gene 281

Fierce Pharma

JUNE 30, 2023

Shareholders in Alkermes have quelled Sarissa Capital, reelecting seven board members and rejecting three nominees from the activist investor.

97

97

Fierce Pharma

APRIL 10, 2024

Leading AstraZeneca investor defends CEO pay ahead of shareholder vote: FT zbecker Wed, 04/10/2024 - 10:49

57

57

BioPharma Reporter

MARCH 15, 2024

A huge â128 million Series B2 round by German startup Tubulis indicates that the field of antibody-drug conjugates (ADCs) in oncology continues to capture investor imaginations.

Antibody 52

Antibody Drugs Development 52

Bio Pharma Dive

FEBRUARY 14, 2024

The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.

Licensing 166

Licensing Licensing Marketing Drugs 166

pharmaphorum

JUNE 11, 2023

Illumina CEO resigns amid investor pressure Phil.Taylor Sun, 11/06/2023 - 18:30 Bookmark this

97

97

pharmaphorum

JULY 6, 2023

Changing Faces: Agency, consultancy, and investor hires from June 2023 Mike.Hammerton Thu, 06/07/2023 - 07:00 Bookmark this

98

98

Bio Pharma Dive

MARCH 19, 2024

The San Diego-based startup added $157 million in new funding to back a drug for generalized anxiety order that’s now in human testing.

Drugs 180

Drugs 180

Fierce Pharma

JUNE 28, 2023

Activist investor NexPoint Asset Management is trying to derail Paratek's $462 million sale to Novo Holdings and Gurnet Point.

Sales 87

Sales 87

Pharmaceutical Technology

APRIL 23, 2024

At the Swiss Biotech Day conference, key opinion leaders discussed trends in pharmaceutical partnerships.

130

130

Fierce Pharma

NOVEMBER 7, 2023

Now, the drugmaker has reportedly garnered the attention of activist investor Elliott Management. . | Armed with dwarfism med Voxzogo and hemophilia A gene therapy Roctavian, BioMarin recently turned a corner into profitability after many years operating at a loss.

Gene Therapy 83

Gene Therapy Gene 83

STAT News

MARCH 13, 2023

The granddaddy of activist investors announced Monday morning that he’s taken a stake in Illumina and wants three handpicked directors added to the company’s board. He tends to leave investors in better shape than before he arrived. Now it has to contend with Carl Icahn.

DNA 98

DNA Genetics 98

BioSpace

JUNE 21, 2021

GSK CEO Emma Walmsley may face some contentious opposition from key investors interested in forcing a management change following the planned investor update.

99

99

Drug Discovery World

JULY 4, 2023

Vesalius Biocapital, a life sciences venture capital investor, has closed its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments. The fund has attracted blue chip investors including the European Investment Fund (EIF).

Life Science 52

Life Science Sales Development Medicine 52

pharmaphorum

NOVEMBER 11, 2022

A prominent genetics professor at Stanford University in the US has paid $29 million to investors in Nuredis – a biotech that has now been wound up – after a California court found he misrepresented the company to investors. The post Stanford prof pays investors in defunct biotech Nuredis $29m appeared first on.

Genetics 111

Genetics Drugs Development Gene 111

Fierce Pharma

APRIL 21, 2023

As Bayer's CEO switch nears, activist investor pushes harder for breakup, board changes fkansteiner Fri, 04/21/2023 - 10:25

96

96

pharmaphorum

DECEMBER 14, 2022

Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. The post Changing Faces: agency, consultant, and investor hires from November 2022 appeared first on. Read on for the hires headlines. New CEO joins UBC.

Life Science 98

Life Science Gene Therapy Gene Editing Gene 98